New hope for Tough-to-Treat lymphoma: major trial tests promising drug duo
NCT ID NCT07355283
Summary
This study is testing whether adding a new drug called IMM0306 to a standard medication (lenalidomide) works better than lenalidomide alone for follicular lymphoma that has come back or isn't responding to treatment. It will involve about 198 patients who have already tried at least two other treatments. The main goals are to see if more patients achieve complete remission and how long the treatment keeps the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.